Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.03.2022 | Case report

Cobimetinib/pembrolizumab/vemurafenib

Stevens-Johnson syndrome and anaemia following drug toxicity: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Batinac T, et al. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma. Acta Dermato-Venereologica 102: 1-3, 22 Feb 2022. Available from: URL: http://doi.org/10.2340/actadv.v102.1433 Batinac T, et al. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma. Acta Dermato-Venereologica 102: 1-3, 22 Feb 2022. Available from: URL: http://​doi.​org/​10.​2340/​actadv.​v102.​1433
Metadaten
Titel
Cobimetinib/pembrolizumab/vemurafenib
Stevens-Johnson syndrome and anaemia following drug toxicity: case report
Publikationsdatum
01.03.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-12112-4

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs